VivoSim Labs, INC.
Business
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company providing drug testing and toxicology insights using three-dimensional human tissue models of liver and intestine. The company offers liver toxicology predictive screening, research services, and bespoke investigational toxicology and mechanism-of-action studies to pharmaceutical and biotech partners. VivoSim operates through proprietary 3D bioprinting technology and organoid platforms, leveraging a broad IP portfolio covering tissue designs, bioprinting methods, and manufacturing processes licensed from academic institutions and company-owned patents.
Summary from 10-K filed 2026-07-14
Financials
Consolidated Statement of Income
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Revenues | — | — | |
| Total Revenues | 131,000 | 144,000 | |
| Cost of revenues | 0 | 5,000 | |
| Research and development expenses | 4 | 5 | |
| Selling, general, and administrative expenses | 7 | 8 | |
| Total costs and expenses | 12 | 13 | |
| Loss from Operations | −11 | −13 | |
| Other Income (Expense) | — | — | |
| Loss on issuance of common stock | −3 | 0 | |
| Gain on investment in equity securities | 94,000 | 0 | |
| Gain on sale of asset | 0 | 10 | |
| Interest income | 267,000 | 140,000 | |
| Interest expense | 12,000 | 10,000 | |
| Total Other Income (Expense) | −2 | 10 | |
| Income Tax Expense | 2,000 | 2,000 | |
| Net Loss | −14 | −2 | |
| Comprehensive Loss | −14 | −2 | |
| Net loss per common share basic | −5.35 | −1.7 | |
| Net loss per common share diluted | −5.35 | −1.7 | |
| Weighted average shares used in computing net loss per common share basic | 3 | 1 | |
| Weighted average shares used in computing net loss per common share diluted | 3 | 1 |
Consolidated Balance Sheet
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Assets | — | — | |
| Current Assets | — | — | |
| Cash and cash equivalents | 5 | 11 | |
| Accounts receivable | 32,000 | 30,000 | |
| Escrow receivable | 1 | 0 | |
| Prepaid expenses and other current assets | 557,000 | 789,000 | |
| Total current assets | 7 | 12 | |
| Fixed assets, net | 206,000 | 419,000 | |
| Restricted cash | 143,000 | 143,000 | |
| Operating lease right-of-use assets | 407,000 | 867,000 | |
| Escrow receivable | 0 | 1 | |
| Prepaid expenses and other assets, net | 3,000 | 90,000 | |
| Total assets | 7 | 15 | |
| Liabilities and Stockholders' (Deficit) Equity | — | — | |
| Current Liabilities | — | — | |
| Accounts payable | 1 | 2 | |
| Accrued expenses | 981,000 | 1 | |
| Insurance premium financing liability | 118,000 | 128,000 | |
| Liability to be settled in equity | 218,000 | 218,000 | |
| Operating lease liability, current portion | 447,000 | 521,000 | |
| Total current liabilities | 3 | 4 | |
| Common stock warrant liabilities | 6 | 0 | |
| Operating lease liability, net of current portion | 0 | 421,000 | |
| Total liabilities | 8 | 4 | |
| Commitments and Contingencies (Note 8) | — | — | |
| Stockholders' (Deficit) Equity | — | — | |
| Common stock, $0.001 par value; 200,000,000 shares authorized, 2,894,519 and 1,898,068 shares issued and outstanding at March 31, 2026 and 2025, respectively | 3,000 | 2,000 | |
| Additional paid-in capital | 355 | 353 | |
| Accumulated deficit | −356 | −342 | |
| Accumulated other comprehensive income | — | — | |
| Treasury stock, 3 shares at cost | 0 | 1,000 | |
| Total stockholders' (deficit) equity | −1 | 10 | |
| Total Liabilities and Stockholders' (Deficit) Equity | 7 | 15 |
Consolidated Statement of Cash Flows
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Cash Flows From Operating Activities | — | — | |
| Net loss | −14 | −2 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | — | — | |
| Loss on issuance of common stock | −3 | 0 | |
| Placement agent warrant offering expense | 138,000 | 0 | |
| Gain on previously liquidated equity securities | 94,000 | 0 | |
| Gain on sale of asset | 0 | 10 | |
| Interest accretion on escrow receivable | 14,000 | 0 | |
| Accretion on investments | 0 | 38,000 | |
| Depreciation and amortization | 215,000 | 266,000 | |
| Stock-based compensation | 303,000 | 532,000 | |
| Non-cash lease expense | 460,000 | 432,000 | |
| Inventory write-off | 0 | 798,000 | |
| Increase (decrease) in cash resulting from changes in: | — | — | |
| Accounts receivable | 2,000 | −3,000 | |
| Inventory | 0 | 501,000 | |
| Prepaid expenses and other assets | −670,000 | −253,000 | |
| Accounts payable | −623,000 | 1 | |
| Accrued expenses | −245,000 | 717,000 | |
| Operating lease liability | −495,000 | −452,000 | |
| Net cash used in operating activities | −11 | −9 | |
| Cash Flows From Investing Activities | — | — | |
| Purchases of fixed assets | 0 | 13,000 | |
| Proceeds from sale of asset | 0 | 9 | |
| Purchases of investments | 0 | 3 | |
| Maturities of investments | 0 | 3 | |
| Proceeds from previously liquidated equity securities | 94,000 | 0 | |
| Purchases of equity securities | — | — | |
| Proceeds from sales of equity securities | — | — | |
| Proceeds from disposals of fixed assets | — | — | |
| Liquidation of equity securities | — | — | |
| Net cash provided by investing activities | 94,000 | 9 | |
| Cash Flows From Financing Activities | — | — | |
| Proceeds from issuance of common stock, net | 5 | 9 | |
| Repayment of insurance premium financing liability | 363,000 | 0 | |
| Employee taxes paid related to net share settlement of equity awards | — | — | |
| Proceeds from exercise of stock options | — | — | |
| Purchase of treasury stock | — | — | |
| Net cash provided by financing activities | 4 | 9 | |
| Net (Decrease) Increase in Cash, Cash Equivalents, and Restricted Cash | −6 | 8 | |
| Cash, cash equivalents, and restricted cash at beginning of period | 11 | 3 | |
| Cash, cash equivalents, and restricted cash at end of period | 5 | 11 | |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | — | — | |
| Cash and cash equivalents | 5 | 11 | |
| Restricted cash | 143,000 | 143,000 | |
| Cash, cash equivalents, and restricted cash at end of period | 5 | 11 | |
| Supplemental Disclosure of Cash Flow Information: | — | — | |
| Escrow receivable | 0 | 1 | |
| Income taxes paid | 2,000 | 2,000 | |
| Interest paid | 12,000 | 10,000 | |
| Liability to be settled in equity | 0 | 218,000 | |
| Financed insurance premium exchanged for prepaid insurance | 353,000 | 128,000 | |
| Common stock warrant liabilities | — | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | — | — | |
| Purchases of fixed assets in accounts payable | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is VivoSim Labs, INC.'s CIK number?
VivoSim Labs, INC.'s SEC CIK number is 0001497253 (1497253). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find VivoSim Labs, INC.'s SEC filings?
All of VivoSim Labs, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did VivoSim Labs, INC. last report earnings?
VivoSim Labs, INC. (VIVS) most recently filed an earnings 8-K with the SEC on Apr 2, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000950170-25-048888). This is VivoSim Labs, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is VivoSim Labs, INC.'s most recent earnings 8-K?
VivoSim Labs, INC.'s latest earnings 8-K (Item 2.02) was filed Apr 2, 2025 under accession 0000950170-25-048888. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View VivoSim Labs, INC.'s latest earnings 8-K →
Look up any company's CIK number →